Sustained GLP-1 receptor agonist therapy is linked to greater improvements in A1c levels than DPP-4 inhibitor therapy in patients with type 2 diabetes, a Danish real-world analysis shows.

A recent study published in the Journal of the American Medical Association revealed that the use of sodium-glucose ...

SGLT2 inhibitors showed significantly improved mortality benefits compared with DPP-4 inhibitors in patients with diabetic kidney disease (DKD) in a large target trial emulation study that adds ...

Researchers found that the rate difference of depression was 3.48 per 1000 person-years between GLP-1 RA users and SGLT-2i users. HealthDay News — For older adults with type 2 diabetes (T2D), use of ...

(HealthDay News) — From 2010 to 2014 there was an increase in use of diabetes medications, including sulfonylureas and dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors), among patients with ...

STOCKHOLM -- The sodium glucose co-transporter 2 (SGLT2) class of diabetes medications may offer more protection against diabetic retinopathy as compared with other hypoglycemic agents, an analysis of ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Data derived from: D ...

A collaboration between a drug plan and clinical pharmacists led to nearly 50% of members successfully switching to a preferred dipeptidyl-peptidase-4 inhibitor. Results: Initially, more than 50% of ...

Among the emerging therapeutic strategies for type 2 diabetes (T2D), G protein-coupled receptor 119 (GPR119) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors have demonstrated promise due to ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SGLT2 inhibitors ...

Please provide your email address to receive an email when new articles are posted on . Treatment with sodium-glucose cotransporter-2 inhibitors for type 2 diabetes may reduce the risk for rheumatoid ...

Modestly lower risk for depression seen compared with DPP-4i use, but not compared with SGLT-2i use. (HealthDay News) — For older adults with type 2 diabetes (T2D), use of glucagon-like peptide-1 ...